MLYS - Mineralys Therapeutics, Inc. News

Mineralys Therapeutics Reports New Data Of Analysis From Its Pivotal Phase 3 Launch-HTN Study

Mineralys Therapeutics, Inc. (Nasdaq: MLYS), a biopharmaceutical company focused on developing medic

Mineralys Therapeutics Presents New Data for Lorundrostat at the American Heart Association Hyperten

- New analyses from the pivotal Launch-HTN trial showed that 46% of participants with difficult-to-t

Mineralys (NASDAQ: MLYS) CEO sells 75,000 shares under prearranged plan

What happened Mineralys Therapeutics, Inc. (NASDAQ: MLYS) said Chief Executive Officer and director

Mineralys Therapeutics Announces Presentation of New Lorundrostat Data at the American Society of Ne

RADNOR, Pa., Oct. 02, 2026 (GLOBE NEWSWIRE) -- Mineralys Therapeutics, Inc. (Nasdaq: MLYS), a biopha

Mineralys Therapeutics To Present Five Abstracts At American Heart Association Hypertension Scientif

Mineralys Therapeutics, Inc. (Nasdaq: MLYS), a biopharmaceutical company focused on developing medic

Mineralys Therapeutics Announces Presentation of Lorundrostat Data at American Heart Association Hyp

RADNOR, Pa., Oct. 01, 2026 (GLOBE NEWSWIRE) -- Mineralys Therapeutics, Inc. (Nasdaq: MLYS), a biopha

Mineralys Therapeutics Reports Inducement Awards Under Nasdaq Listing Rule 5635(c)(4)

RADNOR, Pa., Sept. 29, 2026 (GLOBE NEWSWIRE) -- Mineralys Therapeutics, Inc. (Nasdaq: MLYS), a bioph

Mineralys Therapeutics (NASDAQ:MLYS) Director Brian Taylor Slingsby Sells 104,320 Shares of Company

Mineralys Therapeutics, Inc. (NASDAQ: MLYS - Get Free Report) Director Brian Slingsby sold 104,320 s

Mineralys Therapeutics to Participate in the Stifel 2026 Virtual Cardiometabolic Forum

RADNOR, Pa., Sept. 24, 2026 (GLOBE NEWSWIRE) -- Mineralys Therapeutics, Inc. (Nasdaq: MLYS), a bioph

Mineralys Therapeutics To Present New Long-Term Efficacy And Safety Data From Ongoing Transform-HTN

Mineralys Therapeutics, Inc. (NASDAQ:MLYS), a biopharmaceutical company focused on developing medici

Mineralys Therapeutics' Transform-HTN Open-Label Extension Trial Data Selected for Late-Breaking Pre

RADNOR, Pa., Sept. 23, 2026 (GLOBE NEWSWIRE) -- Mineralys Therapeutics, Inc. (Nasdaq: MLYS), a bioph

Mineralys Therapeutics (NASDAQ:MLYS) Insider Eric Warren Sells 7,438 Shares

Mineralys Therapeutics, Inc. (NASDAQ: MLYS - Get Free Report) insider Eric Warren sold 7,438 shares

Mineralys Therapeutics Reports Inducement Awards Under Nasdaq Listing Rule 5635(c)(4)

RADNOR, Pa., Sept. 21, 2026 (GLOBE NEWSWIRE) -- Mineralys Therapeutics, Inc. (Nasdaq: MLYS), a bioph

Insider Selling: Mineralys Therapeutics (NASDAQ:MLYS) Director Sells $85,740.00 in Stock

Mineralys Therapeutics, Inc. (NASDAQ: MLYS - Get Free Report) Director Daphne Karydas sold 3,000 sha

Mineralys Therapeutics Reports Inducement Awards Under Nasdaq Listing Rule 5635(c)(4)

RADNOR, Pa., Sept. 09, 2026 (GLOBE NEWSWIRE) -- Mineralys Therapeutics, Inc. (Nasdaq: MLYS), a bioph

Greenland Capital Management LP Sells 53,500 Shares of Mineralys Therapeutics, Inc. $MLYS

Greenland Capital Management LP reduced its holdings in Mineralys Therapeutics, Inc. (NASDAQ: MLYS)

seekingalpha.com

Mineralys: Why I'm Making Stock A Buy Ahead Of Hypertension Approval Decision

Mineralys Therapeutics, Inc. is upgraded to Buy, with lorundrostat poised for FDA approval in Decemb

Canada Pension Plan Investment Board Buys New Holdings in Mineralys Therapeutics, Inc. $MLYS

Canada Pension Plan Investment Board bought a new position in shares of Mineralys Therapeutics, Inc.

BlackRock Inc. Buys New Position in Mineralys Therapeutics, Inc. $MLYS

BlackRock Inc. purchased a new position in shares of Mineralys Therapeutics, Inc. (NASDAQ: MLYS) dur

Mineralys Therapeutics to Participate in the Wells Fargo 21st Annual Healthcare Conference

RADNOR, Pa., Aug. 26, 2026 (GLOBE NEWSWIRE) -- Mineralys Therapeutics, Inc. (Nasdaq: MLYS), a biopha

Mineralys Therapeutics Reports Inducement Award Under Nasdaq Listing Rule 5635(c)(4)

RADNOR, Pa., Aug. 13, 2026 (GLOBE NEWSWIRE) -- Mineralys Therapeutics, Inc. (Nasdaq: MLYS), a biopha

seekingalpha.com

Mineralys Therapeutics, Inc. (MLYS) Q2 2026 Earnings Call Transcript

marketbeat.com

Mineralys Therapeutics Q2 Earnings Call Highlights

Mineralys Therapeutics NASDAQ: MLYS said it is continuing commercial-launch preparations for lorundr

7 Health Care Stocks With Whale Alerts In Today's Session

Reported Sunday, Mineralys Therapeutics Presents Late-Breaking Data At ENDO 2026 Showing Lorundrosta

– Lorundrostat was associated with significant reductions in heart failure risk biomarkers in a prot

Mineralys to Present New Trial Data at ENDO 2026, Proteomic Analysis Selected for Late-Breaking ENDO

Mineralys Therapeutics, Inc. (NASDAQ:MLYS), a biopharmaceutical company focused on developing medici

12 Health Care Stocks Moving In Wednesday's Intraday Session

Mineralys Prices $150M Stock Offering Of 5.66M Shares At $26.50/Share, To Use Share Sale Proceeds fo

Mineralys Therapeutics, Inc. (NASDAQ:MLYS), a biopharmaceutical company focused on developing medici

AstraZeneca Scores Key FDA Wins Across Cardiovascular And Oncology Portfolios

AstraZeneca wins FDA approvals for Baxfendy in hypertension and Enhertu in early HER2-positive breas

Earnings Scheduled For May 6, 2026

Mineralys Therapeutics Q1 EPS $(0.47), Inline

Mineralys Therapeutics (NASDAQ:MLYS) reported quarterly losses of $(0.47) per share which met the an

B of A Securities Maintains Buy on Mineralys Therapeutics, Raises Price Target to $51

B of A Securities analyst Greg Harrison maintains Mineralys Therapeutics (NASDAQ:MLYS) with a Buy

Mineralys Therapeutics Q4 EPS $(0.40) Beats $(0.58) Estimate

Mineralys Therapeutics (NASDAQ:MLYS) reported quarterly losses of $(0.40) per share which beat the a

Earnings Scheduled For March 12, 2026

Mineralys Therapeutics Says FDA Accepts NDA For Lorundrostat For Treatment Of Adult Patients With Hy

– The FDA assigned a PDUFA target action date of December 22, 2026 –– The NDA is based on positive d

Stifel Maintains Buy on Mineralys Therapeutics, Raises Price Target to $52

Stifel analyst Annabel Samimy maintains Mineralys Therapeutics (NASDAQ:MLYS) with a Buy and raise

Mineralys Therapeutics' Phase 3 Launch-HTN Trial Of Lorundrostat Featured In JAMA's Inaugural "Resea

– Launch-HTN, the largest trial of an aldosterone synthase inhibitor conducted among participants wi

HC Wainwright & Co. Maintains Buy on Mineralys Therapeutics, Raises Price Target to $56

HC Wainwright & Co. analyst Matthew Caufield maintains Mineralys Therapeutics (NASDAQ:MLYS) w

Wells Fargo Maintains Overweight on Mineralys Therapeutics, Raises Price Target to $55

Wells Fargo analyst Mohit Bansal maintains Mineralys Therapeutics (NASDAQ:MLYS) with a Overweight

Mineralys Therapeutics Q3 EPS $(0.52) Beats $(0.65) Estimate

Mineralys Therapeutics (NASDAQ:MLYS) reported quarterly losses of $(0.52) per share which beat the a

Earnings Scheduled For November 10, 2025

Reported Friday, Mineralys Therapeutics Showcases Broad Clinical Potential of Lorundrostat Across Ca

– Late-breaking presentation of Explore-CKD trial at ASN Kidney Week –– Pivotal Phase 3 Launch-HTN t

Uncovering Potential: Mineralys Therapeutics's Earnings Preview

HC Wainwright & Co. Maintains Buy on Mineralys Therapeutics, Raises Price Target to $52

HC Wainwright & Co. analyst Matthew Caufield maintains Mineralys Therapeutics (NASDAQ:MLYS) w

Mineralys Therapeutics Presents Phase 2 Explore-CKD Trial Of Lorundrostat At ASN Kidney Week 2025

~ Late-breaking Phase 2 trial data evaluating the safety and efficacy of 25 mg of lorundrostat in pa

Wells Fargo Maintains Overweight on Mineralys Therapeutics, Raises Price Target to $50

Wells Fargo analyst Mohit Bansal maintains Mineralys Therapeutics (NASDAQ:MLYS) with a Overweight

Goldman Sachs Maintains Buy on Mineralys Therapeutics, Raises Price Target to $52

Goldman Sachs analyst Richard Law maintains Mineralys Therapeutics (NASDAQ:MLYS) with a Buy and r

HC Wainwright & Co. Reiterates Buy on Mineralys Therapeutics, Maintains $42 Price Target

HC Wainwright & Co. analyst Matthew Caufield reiterates Mineralys Therapeutics (NASDAQ:MLYS)

Mineralys Therapeutics Presents Subgroup Data From Phase 3 Launch-HTN Trial At AHA 2025, Highlightin

~Pivotal Launch-HTN trial of novel aldosterone synthase inhibitor lorundrostat enrolled a diverse ra